Disc Medicine Q2 Loss Misses Estimates by 28%; Cash Runway into 2029 and Key Pipeline Milestones on Track
IRON sits 85% above its 52-week low of $40.
Summary
Disc Medicine's Q2 loss of $1.54 per share missed estimates by 28%, but $718 million in cash provides runway into 2029. The FDA aligned that the Phase 3 APOLLO study can support a CRL response, with topline data due in Q4 2026. Initial data from the RESTORE-PV Phase 2 study is now expected in Q3 2026.
Key Events · Earnings and Guidance · IRON
-
Q2 Loss Misses Consensus
Net loss of $59.5 million, or $1.54 per share, compared to consensus estimate of ~$1.20 per share. The miss was driven by higher R&D and SG&A expenses to support pipeline advancement.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities totaled $717.7 million as of June 30, 2026, expected to fund operations into 2029 — well beyond key catalysts including the APOLLO Phase 3 readout and potential FDA decision.
-
FDA Alignment on Bitopertin Path
Completed Type A meeting with FDA; agency aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for the CRL response and potentially support traditional approval. Topline data expected in Q4 2026.
-
Pipeline Catalysts Accelerating
RESTORE-PV Phase 2 study of DISC-3405 fully enrolled with initial data now expected in Q3 2026 (ahead of schedule). End-of-Phase 2 meeting for selcodebart in myelofibrosis anticipated by year-end 2026.
Analysis · IRON · Life Sciences
Disc Medicine posted a Q2 net loss of $1.54 per share, well below the consensus estimate of ~$1.20, as higher operating costs fueled pipeline advancement. Despite the miss, the company closed the quarter with $718 million in cash, extending its runway into 2029—comfortably past the anticipated APOLLO Phase 3 topline readout in Q4 2026 and a potential FDA decision by mid-2027. The FDA's alignment that APOLLO can serve as the basis for the CRL response de-risks the bitopertin regulatory path. Additional pipeline catalysts are now closer: initial data from the fully enrolled RESTORE-PV Phase 2 study is expected in Q3 2026, and an end-of-Phase 2 meeting for selcodebart in myelofibrosis is anticipated by year-end. The earnings miss is a near-term negative, but the strong cash position and multiple upcoming data readouts keep the investment thesis intact.
At the time of this filing, IRON was trading at $73.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $40.00 to $99.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.